A Comparison of Post Phacoemulsification Aqueous Flare in Patients Using Ketorolac 0.45% 2 Times Daily (BID) and Bromfenac 0.09% 2 Times Daily (BID)

Completed · Phase 4

Conditions studied: Post Operative Anterior Chamber Inflammation (Flare)

In brief

Approximately 50 patients undergoing cataract surgery will be randomized in an even allocation (1:1) into two treatment groups, either ketorolac 0.45% BID or bromfenac 0.09% BID. Patients will be instructed to begin dosing study medication in the operative eye the day before surgery and continue dosing until day 14. KOWA flare measurements will be performed at postoperative day one and postoperative day 14. The amount of anterior chamber inflammation (flare) will be objectively measured.

Key facts

Study ID

NCT01023724

Run by

Bucci Laser Vision Institute

People needed

50

Starts

2009-12-01

Expected to finish

2010-02-01

Last updated by the study team

2011-08-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Subjects must be 18 years of age or older
• Scheduled for cataract surgery by phacoemulsification
• Subject must be willing to comply with all study requirements and be willing to give informed consent

You may not qualify if…

• Any subject that has a history of uveitis or active iritis
• Subject can have no previous intraocular surgery with the exception of refractive surgery. but not within 6 months
• No ocular use of prostaglandins within 2 weeks of surgery
• Use of oral, injectable or topical steroids,nonsteroidal anti-inflammatory drugs (NSAIDs) or immunosuppressants within 14 days prior to surgery
• Contraindications to NSAIDs
• Active ocular infection

Where it is running

• Bucci Laser Vision Institute — Wilkes-Barre, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.